- Home
- ONCO vs VCIG Comparison
ONCO vs VCIG Comparison
Compare ONCO & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | VCIG |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.0M |
| IPO Year | 2022 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ONCO | VCIG |
|---|---|---|
| Price | $1.65 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 55.1K | ★ 1.8M |
| Earning Date | 11-13-2025 | 01-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.98 |
| Revenue | $1,223,751.00 | ★ $32,903,041.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.61 |
| Revenue Growth | N/A | ★ 24.77 |
| 52 Week Low | $1.37 | $0.51 |
| 52 Week High | $88.40 | $1,290.00 |
Technical Indicators
Market Signals| Indicator | ONCO | VCIG |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 35.08 |
| Support Level | $1.37 | $0.51 |
| Resistance Level | $1.71 | $0.68 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 28.00 | 23.44 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.